Why Attend
With an increasing number of projects entering the pipeline both clinically and pre-clinically aimed at targeting "undruggable" transcription factors, the industry is ready to develop further insight into the commercialization of TF-based therapeutics within oncology and other disease settings. Harnessing functional biology and translational research to evaluate which strategies - including PPI inhibitors, TRAFTACs and RNA modulators - are most effective in targeting these elusive proteins is crucial to stay ahead of the curve!
The Transcription Factor Drug Development Congress is one of a kind!
For the second year running, we will bring together leading industry players within large pharma and biotech, along with expert academics in transcriptomics, epigenetics, and oncology drug discovery. With a year of virtual events under our belt, our streamlined platform will provide an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable. Use 1-2-1 meetings, interactive roundtables and discussions as well as networking roulette to hear strategies that will help you overcome the structural biology, pharmacology, and chemical obstacles in the design and development of TF-based therapeutics.
Here’s a sneak peek at our 2021 offering:
- Understand how chromatin remodelling machinery is involved in DNA binding of the transcriptome and use this to inform targeted epigenetic therapies
- Analyse hot-off-the-press approaches to targeting myc, STAT, p53 and more including TRAFTACs, protein degraders, CPPs and PPI inhibitors
- Learn how to build effective collaborations between academic labs, biotech and pharma and get insight into transcriptome and epigenetic focused tool development
PARTNER WITH US
Based on your objectives, we can create bespoke packages designed specifically for you. Opportunities predominantly lie in 3 main categories: Thought Leadership, Branding, and Networking.
Interested in a media partnership?
We'd love to hear from you and how we can support one another to connect with the industry. Contact [email protected]
Talk to Our Speakers About
- Assay development
- TF-inhibitor PK determination
- PPI inhibitor and PROTAC-based degrader development
- Modulators of transcription factor gene expression
- Risk vs benefit; understanding the risks of TF-based therapeutics in normal cells
- Success stories in targeting transcription factors
- TF-inhibitor-kinase inhibitor combinations and targeting TF RNA
- Overcoming protein-DNA and protein-protein binding challenges
- Strategies to identify new TF targets
- Case studies from within the clinic
Speakers
Liandong Ma
Charles Lin
Laura Soucek
Kusal Sumarasinghe
Giorgio Galli
Asad Taherbhoy
Asad Taherbhoy is a Principal Scientist and Team Leader at Foghorn Therapeutics, a company that is developing therapies designed to modulate the chromatin regulatory system. His team is primarily focused on understanding and drugging BAF’s interaction with transcription factors using an array of biochemical and biophysical approaches. Before joining Foghorn, Asad worked on drugging the E3 ligase space at Nurix Therapeutics. Asad carried out his PhD work at St Jude Children’s Research Hospital in the lab of Brenda Schulman and completed his post-doctoral fellowship at Genentech – understanding the various facets of the Ubiquitin and Ubiquitin-like protein pathways.
David Weinstock
Dr. David Weinstock is the Lavine Family Professor at Dana-Farber Cancer Institute and a Professor of Medicine and Pediatrics Harvard Medical School. He completed fellowship training in Medical Oncology and Infectious Diseases at Memorial Sloan-Kettering Cancer Center. He joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital in 2008, where he is a medical oncologist and directs the Weinstock Laboratory, a translational research program focused on novel therapeutics for lymphoid malignancies. He developed the Public Repository of Xenografts (http://www.PRoXe.org), which shares >800 patient-derived xenograft models around the world. He leads the Leukemia Program for the Dana-Farber/Harvard Cancer Center.
David Drewry
Mario Iurlaro
I was born in the seaside city of Taranto, in the south of Italy. I studied Molecular Biotechnologies in Bologna, with 1 year spent at the University of Oxford for my MSc internship. Tired of good weather and great food, for my PhD I moved to Cambridge, UK, where I investigated DNA methylation dynamics in early mammalian development and the biological function of novel DNA modifications. I am currently studying the mechanisms regulating the interaction between chromatin modifications, nucleosome remodelers and transcription factor binding. I enjoy obscure movies, travelling and the NBA playoffs.
Lindsay Pino
I’m a postdoctoral researcher with over a decade of experience in developing mass spectrometry proteomics methods for studying human disease. I’ve trained at the Broad Institute, the University of Washington, and most recently the University of Pennsylvania. My focus is on developing techniques for quantitative proteomics and in particular I’m interested in the challenges associated with scaling-up quantitative proteomics experiments. Lately, I’ve been working on expanding these techniques to target dynamic systems including protein turnover, epigenetics, and protein interactions.
Outside of research, I am a runner, dog owner, and hiker. Although I completed my first full marathon in 2015, I mostly stick to 5-10k’s with my shelter dog now. I’m most at home in the mountains, especially backpacking. My latest hobby is perfecting my macaron recipe, thanks to the Great British Bake-Off.
Angela Koehler
Jun Qin
Melinda Day
Tanaz Sharifnia
Tanaz Sharifnia is a research scientist and investigator in the Chemical Biology and Therapeutics Science Program at the Broad Institute of Harvard and MIT. Her research interests include applying systematic functional genomic and small-molecule-based approaches to discover and target cancer vulnerabilities. Working in close partnership with other scientists, clinicians, a medical research foundation, and patients, she seeks to translate basic research insights into new therapies for patients with intractable cancers. Dr. Sharifnia received her Ph.D. in the field of cancer genomics from Harvard University.
Anjana Rao
Rajwinder Lehal
https://www.cellestia.com/about-us/
Allan Jordan
POSTER SESSION
Looking to showcase your recent work to the drug development community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the virtual event, you need to be registered as a delegate. Please note that there are limited spaces available, this will be assigned on a first come first served basis (subject to checks and successful registration). At the virtual congress, your presentation will be displayed in a dedicated poster 'area'. The poster presentation will take place after the lunch break on day one.
Poster abstract submission deadline is on June 25th 2021. Abstracts received after this time may not be accepted, so please submit you abstracts as soon as possible! Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
For more information please contact [email protected]
Submit your poster here.
Attendees From Our Undruggables Series
Download the Agenda
We're thrilled to share the full program for the second iteration of the Transcription Factor Drug Development Congress with you.
We will once again bring together leading industry players within large pharma and biotech along with expert academics in the oncology drug discovery space – providing an open forum to facilitate the sharing of in vitro and in vivo data, as well as build a deeper understanding of transcriptional machinery to make the ‘undruggable’ druggable.
We hope you can make it!
Download the full agenda here
Event Partner
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket price will increase in
— —
We're going digital!
Kisaco Research is committed to providing attendees across all of our events with the best possible experience, it’s for this reason we’ve decided to go digital and embrace the amazing new technology that enables us to deliver a virtual event.
Here’s what we think are the biggest benefits of going digital, and how you can make best use of your event experience:
Top 10 benefits of virtual events
- Tailor Your Agenda – with sessions spanning across multiple days, design your own agenda based on who you want to hear from and what will be most useful to your business.
- Improved Audience Visibility – you can see exactly who is registered to attend the event and when they’re online – make that valuable connection in real-time!
- On-Demand Content – missed a session or couldn’t tune in that day? That’s fine, sessions will be available to listen to for 2 months post event. That also means you can listen to your favourite speaker multiple times.
- High Quality Speakers – this doesn’t change, whether we run a live event or a virtual one, we recruit industry leading, insightful speakers to inspire.
- More Networking Opportunities – do you sometimes miss the one person you were hoping to meet at live events? With virtual events you can instant message them, add time into their diary, and email them, making target lead gen easier than ever!
- Get More Involved – virtual events offer many more interactive opportunities than live events; participate in live polls, live Q&A and live panel discussions – helping you build you personal brand and your business connections.
- Save Time & Money – tune into an event from the comfort of your own home, no need to travel overseas, spend time away from loved ones and spend your companies money! This makes lead gen and knowledge sharing much more cost efficient.
- Increased Content – we can run more sessions at one time without the constraints of venue capacities, meaning we can provide you with more valuable content in one go.
- Diverse Branding Opportunities – for those looking to partner on the virtual events, there’s lots of branding opportunities through different booth formats, banners, logo placement, thought leadership etc.
- Insights – using analytics, we can help you benchmark stay head of industry trends. We can also share audience insights on job titles, seniority and geography of attendees, so you know this is the right event to match your business needs.
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.